Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 159

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Daratumumab in Intermediate/High-risk Smoldering Multiple Myeloma: Final Analysis of CENTAURUS

Blood blood.2024025897.

https://doi.org/10.1182/blood.2024025897

Published: 2024

Includes: Supplemental data

Journal Articles

Single Center Institutional Experience and Outcomes Administering Both Anti-BCMA and Anti-GPRC5D Bispecific T-Cell Engagers

Shree Allada, Vikas A. Gupta, Craig C. Hofmeister, Jonathan L. Kaufman, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka, Nisha S. Joseph

Blood (2024) 144 (Supplement 1): 7861.

https://doi.org/10.1182/blood-2024-210996

Published: 2024

Journal Articles

Impact of Self-Identified Race on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients Receiving Induction Therapy with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)

Nisha S. Joseph, Shruti Gupta, Jonathan L. Kaufman, Sara Dicamillo, Danielle Roberts, Vikas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka

Blood (2024) 144 (Supplement 1): 7870.

https://doi.org/10.1182/blood-2024-211988

Published: 2024

Journal Articles

Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes

Cindy Varga, Myra Robinson, Vikas Gupta, Craig C. Hofmeister, Ajay K. Nooka, Jonathan L. Kaufman, Madhav V. Dhodapkar, Sagar Lonial, Shanice Borden, Christopher Ferreri, Barry Paul, Shebli Atrash, Manisha Bhutani, Peter M. Voorhees, Nisha S. Joseph

Blood (2024) 144 (Supplement 1): 4702.

https://doi.org/10.1182/blood-2024-204388

Published: 2024

Journal Articles

Feasibility and Target AUC Accuracy of Personalized High Dose Melphalan in Myeloma

Blood (2024) 144 (Supplement 1): 1993.

https://doi.org/10.1182/blood-2024-205614

Published: 2024

Journal Articles

National Healthtree Survey on Pain and Opioid Use Patterns and Perceptions Among Patients with Multiple Myeloma

Karen Sweiss, Jay R. Hydren, Jorge Arturo Hurtado Martinez, Mason S. Barnes, Pritesh Patel, Douglas W Sborov, Jennifer M. Ahlstrom, Lisa Sharp, Craig C. Hofmeister

Blood (2024) 144 (Supplement 1): 283.

https://doi.org/10.1182/blood-2024-210314

Published: 2024

Journal Articles

First Ever National Survey on Patient-Reported Efficacy and Safety of Cannabis in Patients with Multiple Myeloma

Karen Sweiss, Jay R. Hydren, Jorge Arturo Hurtado Martinez, Mason S. Barnes, Pritesh Patel, Douglas W. Sborov, Jennifer M. Ahlstrom, Lisa Sharp, Craig C. Hofmeister

Blood (2024) 144 (Supplement 1): 5144.

https://doi.org/10.1182/blood-2024-210437

Published: 2024

Journal Articles

Serum Free Light Chain Ratio Is Inversely Proportional to the Egfr, and Has Been Increasing over the Last Decade

Gabriel Najarro, Vikas A. Gupta, Nisha S. Joseph, Jonathan L. Kaufman, Ajay K. Nooka, Madhav V. Dhodapkar, Sagar Lonial, Craig C. Hofmeister

Blood (2024) 144 (Supplement 1): 5142.

https://doi.org/10.1182/blood-2024-202078

Published: 2024

Journal Articles

A Slow-Go Treatment in Newly Diagnosed AL Amyloidosis with Severe Cardiomyopathy

Craig C. Hofmeister, Vikas A. Gupta, Nisha S. Joseph, Sagar Lonial, Madhav V. Dhodapkar, Ajay K. Nooka, Jonathan L. Kaufman

Blood (2024) 144 (Supplement 1): 4672.

https://doi.org/10.1182/blood-2024-203485

Published: 2024

Journal Articles

Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2

Shannon M Matulis, Robert M Chavez, Rebecca Owens, Arun P Wiita, Mala Shanmugam, Ricardo De Matos Simoes, Constantine S Mitsiades, Nisha S. Joseph, Craig C. Hofmeister, Jonathan L. Kaufman, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka, Vikas A. Gupta, Jonathan D. Licht, Benjamin G. Barwick, Lawrence H. Boise

Blood (2024) 144 (Supplement 1): 4663.

https://doi.org/10.1182/blood-2024-210441

Published: 2024

Journal Articles

A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma

Craig C. Hofmeister, Vikas A. Gupta, Jonathan L. Kaufman, Ajay K. Nooka, Nisha S. Joseph, Sagar Lonial, Madhav V. Dhodapkar

Blood (2024) 144 (Supplement 1): 255.

https://doi.org/10.1182/blood-2024-202102

Published: 2024

Journal Articles

Survival of Multiple Myeloma Patients in Epic Cosmos Confounded By Death Reporting

Craig C. Hofmeister, Mingyuan Zhang, Vikas A. Gupta, Nisha S. Joseph, Jonathan L. Kaufman, Ajay K. Nooka, Madhav V. Dhodapkar, Sagar Lonial, Douglas W. Sborov

Blood (2024) 144 (Supplement 1): 5152.

https://doi.org/10.1182/blood-2024-202100

Published: 2024

Journal Articles

Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM)

Nisha S. Joseph, Jonathan L. Kaufman, Craig C. Hofmeister, Vikas A. Gupta, Bryan J Burton, Roseann M Pruitt, Ajay K. Nooka, Madhav V. Dhodapkar, Sagar Lonial

Blood (2024) 144 (Supplement 1): 1983.

https://doi.org/10.1182/blood-2024-210335

Published: 2024

Journal Articles

Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with Early Progression Following Induction with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)

Lilly Gu, Nisha S. Joseph, Vikas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka, Jonathan L. Kaufman

Blood (2024) 144 (Supplement 1): 3780.

https://doi.org/10.1182/blood-2024-211474

Published: 2024

Journal Articles

Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies

Lorenzo Cani, Sara A. Scott, Nisha S. Joseph, Craig C. Hofmeister, Vikas A. Gupta, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka, Jonathan L. Kaufman

Blood (2024) 144 (Supplement 1): 3311.

https://doi.org/10.1182/blood-2024-206155

Published: 2024

Journal Articles

Efficacy and Safety of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM): Final Analysis of the Phase 2 Centaurus Study

Ola Landgren, Ajai Chari, Yael C. Cohen, Andrew Spencer, Peter M. Voorhees, Irwindeep Sandhu, Matthew W. Jenner, Dean Smith, Michele Cavo, Niels WCJ van de Donk, Meral Beksac, Philippe Moreau, Hartmut Goldschmidt, Linlin Sha, Liang Li, Els Rousseau, Robyn Dennis, Robin Carson, Craig C. Hofmeister

Blood (2023) 142 (Supplement 1): 210.

https://doi.org/10.1182/blood-2023-181765

Published: 2023

Journal Articles

Free from Drug Therapy in Multiple Myeloma (FREEDMM): MRD-Based Cessation of Maintenance

Ana Maria Avila Rodriguez, Danny Hadidi, Craig C. Hofmeister, John Quigley, Maria Zappia, Maxim Frolov, Elizaveta Benevolenskaya, Matias Eugenio Sanchez, Shrihari Kadkol, Douglas Sborov, Damiano Rondelli, Chukwuemeka Uzoka, Karen Sweiss

Blood (2023) 142 (Supplement 1): 3395.

https://doi.org/10.1182/blood-2023-190011

Published: 2023

Journal Articles

Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)

Nisha S. Joseph, Jonathan L. Kaufman, Sara Dicamillo, Danielle Roberts, Vikas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Lawrence H. Boise, Sagar Lonial, Ajay K. Nooka

Blood (2023) 142 (Supplement 1): 647.

https://doi.org/10.1182/blood-2023-187339

Published: 2023

Journal Articles

Selinexor, Ixazomib, Pomalidomide and Dexamethasone in Functionally High-Risk Multiple Myeloma: Results from the Myeloma Developing Regimens Using Genomics (MyDRUG) Sub-Protocol Y3

Joshua Richter, Jeffrey A. Zonder, Nitya Nathwani, Giada Bianchi, Craig C. Hofmeister, Ravi Vij, Matthew Pianko, Gurbakhash Kaur, Malin Hultcrantz, Katie Wozniak, Mercedes Martillo, Hearn Jay Cho, Shaji Kunnathu Kumar

Blood (2023) 142 (Supplement 1): 3387.

https://doi.org/10.1182/blood-2023-184949

Published: 2023

Journal Articles

Efficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma

Jonathan L. Kaufman, Nisha S. Joseph, Vikas A. Gupta, Sara Dicamillo, Danielle Roberts, Craig C. Hofmeister, Madhav V. Dhodapkar, Ajay K. Nooka, Sagar Lonial, Lawrence H. Boise

Blood (2023) 142 (Supplement 1): 4699.

https://doi.org/10.1182/blood-2023-181783

Published: 2023

NARROW

Efficacy and Safety of Daratumumab in Intermediate/High-risk Smoldering Multiple Myeloma: Final Analysis of CENTAURUS

Single Center Institutional Experience and Outcomes Administering Both Anti-BCMA and Anti-GPRC5D Bispecific T-Cell Engagers

Impact of Self-Identified Race on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients Receiving Induction Therapy with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)

Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes

Feasibility and Target AUC Accuracy of Personalized High Dose Melphalan in Myeloma

National Healthtree Survey on Pain and Opioid Use Patterns and Perceptions Among Patients with Multiple Myeloma

First Ever National Survey on Patient-Reported Efficacy and Safety of Cannabis in Patients with Multiple Myeloma

Serum Free Light Chain Ratio Is Inversely Proportional to the Egfr, and Has Been Increasing over the Last Decade

A Slow-Go Treatment in Newly Diagnosed AL Amyloidosis with Severe Cardiomyopathy

Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2

A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma

Survival of Multiple Myeloma Patients in Epic Cosmos Confounded By Death Reporting

Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM)

Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with Early Progression Following Induction with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)

Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies

Efficacy and Safety of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM): Final Analysis of the Phase 2 Centaurus Study

Free from Drug Therapy in Multiple Myeloma (FREEDMM): MRD-Based Cessation of Maintenance

Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)

Selinexor, Ixazomib, Pomalidomide and Dexamethasone in Functionally High-Risk Multiple Myeloma: Results from the Myeloma Developing Regimens Using Genomics (MyDRUG) Sub-Protocol Y3

Efficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only